Private Wealth Partners LLC Raises Holdings in Novo Nordisk A/S (NYSE:NVO)

Private Wealth Partners LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 48.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 49,300 shares of the company's stock after purchasing an additional 16,097 shares during the period. Private Wealth Partners LLC's holdings in Novo Nordisk A/S were worth $4,241,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. OLD National Bancorp IN raised its position in shares of Novo Nordisk A/S by 30.5% during the third quarter. OLD National Bancorp IN now owns 4,399 shares of the company's stock valued at $524,000 after buying an additional 1,027 shares during the last quarter. Ledyard National Bank raised its position in shares of Novo Nordisk A/S by 6.2% during the third quarter. Ledyard National Bank now owns 4,285 shares of the company's stock valued at $510,000 after buying an additional 250 shares during the last quarter. Waldron Private Wealth LLC boosted its stake in Novo Nordisk A/S by 44.8% during the third quarter. Waldron Private Wealth LLC now owns 4,141 shares of the company's stock worth $493,000 after buying an additional 1,282 shares during the period. Stanley Laman Group Ltd. purchased a new position in Novo Nordisk A/S during the third quarter worth $282,000. Finally, Weaver Capital Management LLC boosted its stake in Novo Nordisk A/S by 15.3% during the third quarter. Weaver Capital Management LLC now owns 2,298 shares of the company's stock worth $274,000 after buying an additional 305 shares during the period. Institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating for the company. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Stock Up 5.4 %

Shares of NVO stock traded up $4.53 on Friday, hitting $88.27. The stock had a trading volume of 13,022,739 shares, compared to its average volume of 9,187,441. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average price of $86.39 and a 200 day moving average price of $108.48. The company has a market cap of $396.12 billion, a PE ratio of 26.80, a P/E/G ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a one year low of $77.82 and a one year high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.